Nadezhda Kudryavtseva, who suffers from Bechterew's disease, has been self-funding her vital treatment for two years. However, after exhausting family savings, her attempt to obtain the drug through the state has faced bureaucratic and medical hurdles.
Contradictions in diagnoses
After the woman sought assistance from state structures, she encountered inconsistencies in medical data. While some specialists confirm the previously established diagnosis of "ankylosing spondylitis," other doctors find insufficient grounds to confirm it.
According to the patient, taking the prescribed Ranvek at a dosage of 15 milligrams per day has had a positive effect on her condition. As evidence of its effectiveness, she cites MRI data: compared to a 2024 study, bone marrow edema in the sacroiliac joints is no longer visible.
Cost of treatment
At the beginning of 2026, the financial ability to continue therapy was lost. The situation is complicated by the fact that without regular medication, there is a risk of irreversible deterioration of vision.
Context
Bechterew's disease (ankylosing spondylitis) is a chronic condition affecting the spine and joints. Nadezhda Kudryavtseva was diagnosed in 2024 at the "Semya i Zdorovye" private medical center.







